Lykos Therapeutics

Founded in 2014, we are a biotechnology research company aiming to transform mental healthcare. We use evidence-based research to develop investigational psychedelics and therapeutic approaches for mental health conditions, focusing initially on post-traumatic stress disorder (PTSD).

Our work includes clinical research, drug development, and research into psychedelics, plant medicine, PTSD, anxiety, and social anxiety, including Schedule I substances. We operate as a Public Benefit Company.

Our mission is to transform mental healthcare. We envision a world with more mental health treatment options and open conversations, as we recognize the urgent need for innovation. As a Public Benefit Corporation, we focus on positively impacting our people, communities, and society.

Our values are:

• Impact: We set ambitious goals, act boldly, prioritize resources for our mission, measure performance, strive for continuous improvement, and communicate honestly.
• Integrity: We are accountable, earn trust through honesty, uphold commitments, and act as stewards of our work.
• Openness: We are curious, welcome new perspectives, are transparent, and include underrepresented voices.
• Care: We show compassion, are attentive to others’ needs, treat everyone respectfully, and take the time to do our work correctly.

We have a team of 51-200 employees. Our culture is shaped by our status as a Public Benefit Company, which means we prioritize positively impacting our people, communities, and society. We aim to challenge the status quo and inspire change in mental healthcare. Our core values of Impact, Integrity, Openness, and Care guide how we operate and interact.